Novo Nordisk A/S Investigated by the Portnoy Law Firm
LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S (“Novo Nordisk" or the "Company") (NYSE:NVO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via http://portnoylaw.com/novo-nordisk-a-s. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On February 23, 2026, Novo Nordisk issued a press release “announc[ing] headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.” The press release reported that Novo Nordisk’s experimental drug CagriSema failed to achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks.
On this news, Novo Nordisk’s American Depositary Receipt (“ADR”) price fell $7.79 per ADR, or 16.43%, to close at $39.63 per ADR on February 23, 2026.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
